The Diabetes Drug Trying to Do Two Jobs at Once
The Diabetes Drug Trying to Do Two Jobs at Once
Eli Lilly is advancing a combination therapy designed to tackle two of the hardest problems in metabolic disease at the same time: substantial weight loss and meaningful blood-sugar control in people who have both obesity and type 2 diabetes. The candidate, called EloraTZP, pairs the selective amylin receptor agonist eloralintide with tirzepatide (Zepbound/Mounjaro), Lilly’s dual GIP/GLP-1 receptor agonist. In a Phase 2b trial presented at the European Association for the Study of Diabetes (EASD) 2026 meeting, the highest dose of the combination produced average weight loss of up to 23.3% and an A1C reduction of up to 2.9% at 48 weeks—figures that exceeded those achieved with tirzepatide 15 mg alone. On the strength of the data, Lilly plans to start Phase 3 trials in the fourth quarter of 2026.
Why Two Jobs Are Harder Than One
Patients with type 2 diabetes typically lose less weight on incretin-based therapies than people without diabetes. At the same time, many obesity drugs have only modest effects on glycaemia. A single regimen that can deliver large, durable weight loss while also driving clinically important A1C reductions would address both needs without requiring patients to manage separate medications or accept trade-offs between the two outcomes. That is the dual mandate EloraTZP is trying to meet.
How the Combination Works
Tirzepatide already activates two nutrient-stimulated hormone pathways—GIP and GLP-1—that regulate insulin secretion, appetite and gastric emptying. Adding eloralintide brings in a third pathway: amylin, a hormone co-secreted with insulin that promotes satiety and slows gastric emptying. The combination is designed to engage GIP, GLP-1 and amylin receptors with minimal activity at the calcitonin receptor, aiming for additive effects on both weight and glucose without unnecessary off-target signalling.
Phase 2b Results at a Glance
In adults with obesity or overweight and type 2 diabetes, EloraTZP dose combinations produced mean weight loss ranging from roughly 13% to 23.3% at 48 weeks, compared with 14.8% for tirzepatide 15 mg and about 3% for placebo. A1C reductions ranged from 2.2% to 2.9% (from a baseline around 8.1%), versus 2.4% with tirzepatide alone and 0.3% with placebo. All tested combinations of eloralintide plus tirzepatide met the study’s primary and secondary endpoints for weight loss and glycaemic control. Eloralintide monotherapy produced more modest effects, underscoring the value of the combination.
Competitive Context
The metabolic pipeline is crowded with dual and triple agonists and with other amylin-based combinations, including Novo Nordisk’s CagriSema (cagrilintide plus semaglutide). Lilly’s own triple agonist retatrutide is also in late-stage development. EloraTZP’s early data suggest it may set a high bar specifically in the diabetes-plus-obesity population, where weight-loss efficacy is often attenuated. Head-to-head and longer-term trials will be needed to clarify relative positioning on efficacy, tolerability and dosing convenience.
Safety and Next Steps
Detailed safety data from the Phase 2b study will be important for assessing gastrointestinal tolerability and any signals unique to the amylin component. Lilly has indicated that Phase 3 trials will begin before the end of 2026. Those studies will need to confirm the magnitude and durability of both weight and glycaemic benefits, establish the optimal dose, and generate the cardiovascular and other outcome data increasingly expected for metabolic drugs.
Outlook
EloraTZP is a clear example of a diabetes-oriented therapy being engineered to perform two demanding jobs simultaneously: deep weight loss and robust A1C reduction in a population that has historically been difficult to treat on both fronts. The Phase 2b results give the program a strong launch into Phase 3. Whether the combination can sustain its dual performance over longer periods, maintain an acceptable safety profile, and differentiate itself in a rapidly evolving market will determine if it becomes a new standard for patients living with both obesity and type 2 diabetes.
Sources
Anthracite
Found this useful?
